Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol-Myers Squibb”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as...
Levi & Korsinsky is investigating the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (Nasdaq: AMLN) for possible breaches of fiduciary duty and...
Block & Leviton LLP Investigates Amylin Pharmaceuticals, Inc. for Possible Breaches of Fiduciary Duties in Connection with Its Proposed Merger with Bristol-Myers Squibb Company PR...
Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding...
Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc. PR Newswire DALLAS, July 9, 2012 DALLAS, July 9, 2012 /PRNewswire/...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc (“Amylin” or the “Company”...
Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc. PR Newswire BALA CYNWYD, Pa., July 3, 2012 BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of...
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/amln) is investigating potential claims against the board of directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”...
Levi & Korsinsky is investigating the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (Nasdaq: AMLN) for possible breaches of fiduciary duty and...
Harwood Feffer LLP Announces Investigation of Amylin Pharmaceuticals, Inc. PR Newswire NEW YORK, July 2, 2012 NEW YORK, July 2, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
